NCT07183189View on ClinicalTrials.gov

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

576

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2032

Study Completion Date

December 31, 2032

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

SHR-A2009 ; Aumolertinib

SHR-A2009 administered intravenously, Aumolertinib administered orally.

DRUG

Aumolertinib

Aumolertinib administered orally

Trial Locations (1)

510080

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07183189 - A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC | Biotech Hunter | Biotech Hunter